High-consequence pathogen protocol redaction clarification packet approved for restricted dual-use review intake¶

Canonical pattern(s): Approval-gated collaborative artifact release Source Markdown: instances/research/high-consequence-pathogen-protocol-redaction-clarification-packet-approved-for-restricted-dual-use-review-intake.md

Linked pattern(s)¶

• approval-gated-collaborative-artifact-release

Domain¶

Research.

Scenario summary¶

A principal investigator, an institutional biosafety officer, and a secure methods-governance lead are co-producing one governed sensitive-methods redaction clarification packet because a draft protocol supplement for a high-consequence pathogen challenge study now contains procedural detail that may exceed the institution's approved disclosure boundary for aerosolization settings, environmental persistence checks, and scale-up notes. Agents help reconcile protocol revisions, containment annotations, biosafety objections, and approved redaction wording into the shared packet while preserving which disclosure questions remain contested and which residual specificity the human artifact owner accepted explicitly. The workflow ends only when the named research release owner approves that exact packet revision for one bounded restricted dual-use review intake lane, where downstream reviewers may decide whether the supplement can proceed to formal sensitive-methods review or requires narrower technical disclosure. It does not adjudicate dual-use risk, communicate with outside collaborators, or authorize protocol or manuscript submission.

Target systems / source systems¶

• Governed research methods workspace holding the sensitive-methods redaction clarification packet, revision history, objection ledger, and release-manifest state
• Secure protocol repository, pathogen challenge study records, biosafety committee minutes, and containment-control files providing authoritative method text and approved handling constraints
• Supplement draft annotations, red-team disclosure notes, instrument-configuration logs, and unresolved reviewer comments supplying disputed parameter detail, redact-or-retain disagreements, and open caveats
• Dual-use governance policy, restricted intake rules, and access-control systems defining required signers, allowed packet audience, and the one bounded review lane
• Approval-routing, audit, and retention systems preserving superseded packet revisions, held-release causes, accepted residual disagreement, and downstream handoff traceability

Why this instance matters¶

This grounds the pattern in research governance work focused on sensitive-methods disclosure control rather than publication-integrity claims, participant consent wording, or publication-rights provenance. The reusable challenge is collaborative ownership of one high-risk clarification artifact whose exact revision must be approved before it can cross into a bounded dual-use review intake lane, while unresolved disagreements about procedural specificity and redaction sufficiency remain inspectable instead of being polished away. The example stays inside the pattern boundary because dual-use adjudication, collaborator notification, and protocol or manuscript submission remain separate workflows.

Likely architecture choices¶

• Approval-gated execution fits because the clarification packet can be collaboration-ready while still blocked from restricted dual-use intake until the human release owner approves the exact revision.
• Human-in-the-loop control is required because only accountable research and biosafety leaders may accept residual disclosure risk, confirm audience scope, and authorize the packet's release boundary.
• Agents may compare protocol versions, refresh containment evidence links, and maintain the release trace, but they must not decide dual-use acceptability, negotiate external sharing terms, or submit the study materials onward.

Governance notes¶

• The release manifest should bind one exact packet revision, the named restricted dual-use review lane, signer identities, the covered supplement sections, and any residual objections the human release owner accepted explicitly.
• Candidate redactions, aerosolization parameter disputes, scale-up caveats, and containment-assumption conflicts should remain visible in the packet or boundary ledger rather than being normalized away before release.
• Audience scope should stay limited to the approved dual-use intake lane; reuse of the packet for collaborator circulation, funding disclosures, protocol submission, or manuscript packaging should require separate downstream approval.
• If protocol text, biosafety restrictions, or the approved reviewer set changes materially during approval review, the workflow should hold release and supersede the prior packet revision rather than letting stale approval carry forward.

Evaluation considerations¶

• Rate at which restricted dual-use intake accepts the released packet without discovering hidden procedural specificity, stale biosafety evidence, or audience-boundary mistakes
• Time required to keep one collaborative clarification packet synchronized as protocol drafts, reviewer objections, and signer state evolve
• Reliability of binding between the released artifact revision, accepted residual disagreement, supplement-section scope, and the bounded restricted dual-use review lane
• Frequency with which humans reject agent-assisted edits because they drifted into dual-use adjudication, outside-party communication, or protocol or manuscript-submission execution